Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

A Limited-Versus-Extensive Staging Strategy for Small Cell Prostate Cancer.

Syed S, Basourakos SP, Ali FS, Garcia JL, Zurita-Saavedra A, Gong Z.

Am J Clin Oncol. 2019 Nov 21. doi: 10.1097/COC.0000000000000631. [Epub ahead of print]

PMID:
31764016
2.

Pheochromocytoma arising in the settingof adrenal-renal fusion.

Basourakos SP, Dean L, Van Gurp J, Reuter V, Russo P.

Can J Urol. 2019 Oct;26(5):9952-9955.

PMID:
31629446
3.

Active surveillance for prostate and thyroid cancers: evolution in clinical paradigms and lessons learned.

Lowenstein LM, Basourakos SP, Williams MD, Troncoso P, Gregg JR, Thompson TC, Kim J.

Nat Rev Clin Oncol. 2019 Mar;16(3):168-184. doi: 10.1038/s41571-018-0116-x. Review.

PMID:
30413793
4.

β‑catenin nuclear translocation induced by HIF‑1α overexpression leads to the radioresistance of prostate cancer.

Luo Y, Li M, Zuo X, Basourakos SP, Zhang J, Zhao J, Han Y, Lin Y, Wang Y, Jiang Y, Lan L.

Int J Oncol. 2018 Jun;52(6):1827-1840. doi: 10.3892/ijo.2018.4368. Epub 2018 Apr 12.

5.

ATRA increases iodine uptake and inhibits the proliferation and invasiveness of human anaplastic thyroid carcinoma SW1736 cells: Involvement of β-catenin phosphorylation inhibition.

Lan L, Basourakos S, Cui D, Zuo X, Deng W, Huo L, Chen H, Zhang G, Deng L, Shi B, Luo Y.

Oncol Lett. 2017 Dec;14(6):7733-7738. doi: 10.3892/ol.2017.7225. Epub 2017 Oct 19.

6.

Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer models.

Luo Y, Azad AK, Karanika S, Basourakos SP, Zuo X, Wang J, Yang L, Yang G, Korentzelos D, Yin J, Park S, Zhang P, Campbell JJ, Schall TJ, Cao G, Li L, Thompson TC.

Int J Cancer. 2018 May 15;142(10):2163-2174. doi: 10.1002/ijc.31237. Epub 2018 Jan 30.

7.

Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer.

Zhang W, Liu B, Wu W, Li L, Broom BM, Basourakos SP, Korentzelos D, Luan Y, Wang J, Yang G, Park S, Azad AK, Cao X, Kim J, Corn PG, Logothetis CJ, Aparicio AM, Chinnaiyan AM, Navone N, Troncoso P, Thompson TC.

Clin Cancer Res. 2018 Feb 1;24(3):696-707. doi: 10.1158/1078-0432.CCR-17-1872. Epub 2017 Nov 14.

8.

Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer.

Basourakos SP, Davis JW, Chapin BF, Ward JF, Pettaway CA, Pisters LL, Navai N, Achim MF, Wang X, Chen HC, Choi S, Kuban D, Troncoso P, Hanash S, Thompson TC, Kim J.

BJU Int. 2018 Jan;121(1):69-76. doi: 10.1111/bju.13963. Epub 2017 Aug 16.

9.

Active surveillance in prostate cancer: new efforts, new voices, new hope.

Basourakos SP, Hoffman K, Kim J.

BJU Int. 2017 Jul;120(1):4-5. doi: 10.1111/bju.13722. No abstract available.

10.

Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.

Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, Manyam GC, Wu W, Luo Y, Basourakos S, Song JH, Gallick GE, Karantanos T, Korentzelos D, Azad AK, Kim J, Corn PG, Aparicio AM, Logothetis CJ, Troncoso P, Heffernan T, Toniatti C, Lee HS, Lee JS, Zuo X, Chang W, Yin J, Thompson TC.

Sci Signal. 2017 May 23;10(480). pii: eaam7479. doi: 10.1126/scisignal.aam7479.

11.

Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.

Basourakos SP, Li L, Aparicio AM, Corn PG, Kim J, Thompson TC.

Curr Med Chem. 2017;24(15):1586-1606. doi: 10.2174/0929867323666161214114948. Review.

12.

Inhibiting β-catenin expression promotes efficiency of radioiodine treatment in aggressive follicular thyroid cancer cells probably through mediating NIS localization.

Lan L, Basourakos S, Cui D, Zuo X, Deng W, Huo L, Chen L, Zhang G, Deng L, Shi B, Luo Y.

Oncol Rep. 2017 Jan;37(1):426-434. doi: 10.3892/or.2016.5228. Epub 2016 Nov 7.

PMID:
27840971
13.

Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer.

Karantanos T, Karanika S, Wang J, Yang G, Dobashi M, Park S, Ren C, Li L, Basourakos SP, Hoang A, Efstathiou E, Wang X, Troncoso P, Titus M, Broom B, Kim J, Corn PG, Logothetis CJ, Thompson TC.

Oncotarget. 2016 Jul 19;7(29):46321-46334. doi: 10.18632/oncotarget.10113.

14.

The role of portal vein embolization in the surgical management of primary hepatobiliary cancers. A systematic review.

Glantzounis GK, Tokidis E, Basourakos SP, Ntzani EE, Lianos GD, Pentheroudakis G.

Eur J Surg Oncol. 2017 Jan;43(1):32-41. doi: 10.1016/j.ejso.2016.05.026. Epub 2016 Jun 1. Review.

PMID:
27283892
15.

The implications of ageing and life expectancy in prostate cancer treatment.

Kalra S, Basourakos S, Abouassi A, Achim M, Volk RJ, Hoffman KE, Davis JW, Kim J.

Nat Rev Urol. 2016 May;13(5):289-95. doi: 10.1038/nrurol.2016.52. Epub 2016 Mar 22. Review.

PMID:
27001016

Supplemental Content

Loading ...
Support Center